Known targets — ChEMBL curated mechanism
ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4
The experimentally established mechanism targets of Succinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.60 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.60 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.53 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.53 |
| ▸ | FFAR3 | O14843 | 3/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.45 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.45 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | KDM5C | P41229 | 2/20 | 0.41 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Succinic Acid SCHEMBL107799 | 1.00 | — | — | |
| Succinic Acid SCHEMBL21776708 | 1.00 | LMNA (0.60) | LMNAEGLN1ALKBH5SUCNR1MAPK1 | |
| Succinic Acid SCHEMBL29461603 | 0.97 | LMNA (0.56) | LMNAEGLN1ALKBH5SUCNR1MAPK1 | |
| Succinic Acid SCHEMBL27324587 | 0.97 | LMNA (0.56) | LMNAEGLN1ALKBH5SUCNR1MAPK1 | |
| Succinic Acid SCHEMBL30298887 | 0.94 | LMNA (0.53) | LMNAEGLN1ALKBH5SUCNR1MAPK1 | |
| Succinic Acid SCHEMBL155053 | 0.93 | LMNA (0.60) | LMNAEGLN1ALKBH5SUCNR1MAPK1 | |
| Succinic Acid SCHEMBL105373 | 0.93 | — | — | |
| Succinic Acid SCHEMBL18889846 | 0.93 | LMNA (0.60) | LMNAEGLN1ALKBH5SUCNR1MAPK1 | |
| Succinic Acid SCHEMBL151456 | 0.93 | LMNA (0.60) | LMNAEGLN1ALKBH5SUCNR1MAPK1 | |
| Succinic Acid SCHEMBL104934 | 0.93 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115721732-A | Pharmaceutical composition and preparation of antibody-conjugated drug, preparation method and application thereof | 上海复旦张江生物医药股份有限公司 | 2023-03-03 | — | — | CN | claimed |
| EP-4393949-A1 | PHARMACEUTICAL COMPOSITION CONTAINING FUSION PROTEIN | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2024-07-03 | — | — | EP | disclosed |
| CN-118175993-A | Anti-SOST antibody pharmaceutical composition and application thereof | 江苏恒瑞医药股份有限公司 | 2024-06-11 | — | — | CN | disclosed |
| WO-2024114626-A1 | ANTI-HER3 ANTIBODY-DRUG CONJUGATE COMPOSITION AND PHARMACEUTICAL USE THEREOF | 苏州盛迪亚生物医药有限公司 | 2024-06-06 | — | — | WO | disclosed |
| EP-4376809-A1 | ANTI-PD-1 ANTIBODY PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Junshi Biosciences Co., Ltd. (CN) | 2024-06-05 | — | — | EP | disclosed |
| WO-2024109914-A1 | PHARMACEUTICAL COMPOSITION COMPRISING BISPECIFIC ANTIBODY SPECIFICALLY BINDING TO HGFR AND EGFR | 江苏恒瑞医药股份有限公司 | 2024-05-30 | — | — | WO | disclosed |
| EP-4374874-A1 | PHARMACEUTICAL COMPOSITION CONTAINING ANTI-TROP2 ANTIBODY DRUG CONJUGATE AND USE THEREOF | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2024-05-29 | — | — | EP | disclosed |
| EP-4375298-A1 | PHARMACEUTICAL COMPOSITION OF ANTI-ANGPTL3 ANTIBODY OR ANTIGEN BINDING FRAGMENT THEREOF AND ITS APPLICATION | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2024-05-29 | — | — | EP | disclosed |
| CN-117858903-A | Pharmaceutical composition containing anti-PVRIG/TIGIT bispecific antibody | 江苏恒瑞医药股份有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-117642424-A | Pharmaceutical composition containing fusion protein | 江苏恒瑞医药股份有限公司 | 2024-03-01 | — | — | CN | disclosed |
| EP-3639845-A1 | IL-15 PROTEIN COMPLEX PHARMACEUTICAL COMPOSITION AND USES THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2020-04-22 | — | — | EP | disclosed |
| CN-110960490-A | anti-EGFR antibody coupling pharmaceutical composition and application thereof | 江苏恒瑞医药股份有限公司 | 2020-04-07 | — | — | CN | disclosed |
| EP-3626266-A1 | PD-L1 ANTIBODY PHARMACEUTICAL COMPOSITION AND USE THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2020-03-25 | — | — | EP | disclosed |
| US-20200069800-A1 | PD-L1 ANTIBODY PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2020-03-05 | — | — | US | disclosed |
| CN-110732023-A | HER2 antibody pharmaceutical composition and application thereof | 江苏恒瑞医药股份有限公司 | 2020-01-31 | — | — | CN | disclosed |
| CN-110538321-A | CD47 antibody pharmaceutical composition and application thereof | JIANGSU HENGRUI MEDICINE CO | 2019-12-06 | — | — | CN | disclosed |
| CN-110431153-A | A kind of PCSK-9 antibody pharmaceutical compositions and application thereof | JIANGSU HENGRUI MEDICINE COMPANY | 2019-11-08 | — | — | CN | disclosed |
| EP-0298757-B1 | METHOD FOR PREPARING VITAMIN D COMPOUNDS | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1993-10-13 | — | — | EP | disclosed |
| US-4892821-A | HYDROXYLATION USING THE MYCELIUM OF ACTINOMYCETALES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1990-01-09 | — | — | US | disclosed |
| EP-0298757-A1 | Method for preparing vitamin D compounds | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1989-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200069800-A1 | PD-L1 ANTIBODY PHARMACEUTICAL COMPOSITION AND USE THEREOF | PDCD1LG2, CD274, PDCD1 | LMNA 4022/4885EGLN1 4458/4885ALKBH5 3683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.